Skip to content

Harmony Biosciences

US · HRMY #2681 by market cap Listed 2020
32.59 -0.39 -1.18%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 29 in the most recent period (2026/Q3).
  • Total institutional ownership rose 6.3 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
114.31% +6.25pp
Institutions
421 +29
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund75.04%
Hedge Fund13.93%
Private Company13.49%
VC/PE Fund5.90%
Public Company3.18%
Government Pension Fund1.45%
Family Office/Trust0.80%
Sovereign Wealth Fund0.26%
Insurance Company0.17%
Bank/Investment Bank0.12%

Top holders as of 2026-09-30

BlackRock 12.54% · 7.36M sh
Marshman Fund Trust II 10.30% · 6.05M sh
FMR 5.57% · 3.27M sh
American Century Investment Management 5.30% · 3.11M sh
Vanguard Portfolio Management, LLC 5.06% · 2.97M sh
Dimensional Fund Advisors 4.51% · 2.65M sh
Vanguard Capital Management, LLC 3.76% · 2.21M sh
LSV Asset Management 3.75% · 2.21M sh
HBM Healthcare Investments AG 3.66% · 2.15M sh
State Street Global Advisors 3.63% · 2.13M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 24 buys · 23 sells

NameRoleStake
Marshman Fund Trust II -- 10.30%
Sandip Kapadia Former Chief Financial Officer 0.04%
Kumar Budur Executive VP and Chief Medical & Scientific Officer 0.02%
Jeffrey Dayno Chief Executive Officer 0.02%
Andrew Serafin Chief Strategy Officer 0.01%
Adam Zaeske Executive Vice President 0.01%
Stephen Mollichella Senior VP, Controller & Interim Principal Financial Officer 0.00%
Jeffrey Aronin Non-Executive Chairperson 0.00%
R. Graf Independent Director --
Gary Sender Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-17 Kumar Budur Executive VP and Chief Medical & Scientific Officer Derivative Exercise and Sale -38,452 $30.27–43.05
2026-09-17 Kumar Budur Executive VP and Chief Medical & Scientific Officer Intent to Sell (Form 144) -35,852 $42.74
2026-09-16 Kumar Budur Executive VP and Chief Medical & Scientific Officer Intent to Sell (Form 144) -800 $42.21
2026-09-15 Kumar Budur Executive VP and Chief Medical & Scientific Officer Intent to Sell (Form 144) -1,800 $42.17
2026-09-07 Kumar Budur Executive VP and Chief Medical & Scientific Officer Automatic Disposition -11,000 $41.98–42.79
2026-09-07 Kumar Budur Executive VP and Chief Medical & Scientific Officer Derivative Exercise and Sale -22,954 $30.27–43.10
2026-09-03 Kumar Budur Executive VP and Chief Medical & Scientific Officer Intent to Sell (Form 144) -5,500 $41.86
2026-08-06 Valor Management LLC -- Intent to Sell (Form 144) -700,883 $37.90
2026-07-15 Stephen Mollichella Senior VP, Controller & Interim Principal Financial Officer Initial Statement of Beneficial 0 --
2026-07-01 Sandip Kapadia Former Chief Financial Officer Intent to Sell (Form 144) -25,000 $36.96
2026-06-29 Sandip Kapadia Former Chief Financial Officer Intent to Sell (Form 144) -50,000 $36.08
2026-06-25 Sandip Kapadia Former Chief Financial Officer Intent to Sell (Form 144) -45,594 $35.24
2026-06-23 Sandip Kapadia Former Chief Financial Officer Intent to Sell (Form 144) -4,406 $35.02
2026-06-08 Sandip Kapadia Former Chief Financial Officer Intent to Sell (Form 144) -27,960 $33.74
2026-06-04 Sandip Kapadia Former Chief Financial Officer Intent to Sell (Form 144) -2,101 $33.08
2026-06-03 Sandip Kapadia Former Chief Financial Officer Intent to Sell (Form 144) -7,064 $33.02
2026-05-13 R. Graf Independent Director Other Derivative Acquisition +21,872 $30.76
2026-05-13 Gary Sender Independent Director Other Derivative Acquisition +21,872 $30.76
2026-05-13 Linda Szyper Independent Director Other Derivative Acquisition +21,872 $30.76
2026-05-13 Geno Germano Independent Director Other Derivative Acquisition +21,231 $30.76

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.

Harmony Biosciences discussion 0 comments

Add a comment